Douglas W. Pagan - 15 Dec 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc

Role: Chief Financial Officer
Signature: /s/ Douglas Fambrough, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 15 Dec 2021
Net transactions value: -$22,906
Form type: 4
Filing time: 17 Dec 2021, 15:18:31 UTC
Previous filing: 17 Jun 2021
Next filing: 29 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise		+2,050	+32%		8,377	15 Dec 2021	Direct	F1, F2
transaction	DRNA	Common Stock	Tax liability	$22,906	-602	-7.2%	$38.05	7,775	15 Dec 2021	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Restricted Stock Units	Options Exercise	$0	-2,050	-25%	$0.000000	6,150	15 Dec 2021	Common Stock	2,050		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2	Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
F3	Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F4	The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.